Back to the main directory
EarningsReview / Equity
- Capital questions by BNP Paribas
- IPO time by BNP Paribas
- Previewing diversified miners, and debating COVID-19 by BNP Paribas
- Boliden - Keeping the money on the balance sheet by Danske Bank Equity Research
- Swedish Orphan Biovitrum - 2020 a penalty kick for quality growth by Danske Bank Equity Research
- Huhtamaki - Sustainably wrapped growth case by Danske Bank Equity Research
- FY19 postview (+15 questions for management) by BNP Paribas
- Far East Hospitality Trust (FEHT SP) by HSBC
- KDDI Corp (9433 JP) by HSBC
- Itaú BBA on RUMO: 4Q19 – Soft Results, as Expected by Itau
- Itaú BBA on OMA: Strong 4Q19 Margin Expansion, But Bottom-Line Decrease by Itau
- Ping An Bank (000001 CH) by HSBC
- As it says on the tin by BNP Paribas
- PCCW (8 HK) by HSBC
- Swedish Orphan Biovitrum (Buy, TP: SEK275.00) - Gearing up for future growth by DnB Markets
- Boliden (Buy, TP: SEK270.00) - Why we like 2020 despite the miss by DnB Markets
- Hufvudstaden (Hold, TP: SEK200.00) - Market rents key to NAV growth by DnB Markets
- Humana (Buy, TP: SEK68.00) - Two steps forward and one back by DnB Markets
- Sbanken (Buy, TP: NOK83.00) - Margin tailwind offset by cost inflation by DnB Markets
- Betsson (Buy, TP: SEK70.00) - Acquisition and good start to 2020 by DnB Markets
- Seafood - Fat Trout Weekly by DnB Markets
- Nokian Tyres (Sell, TP: EUR26.00) - Price study indicates downside risk by DnB Markets
- Sbanken - Excessive discount by Danske Bank Equity Research
- Medicover - Solid performance already priced in by Danske Bank Equity Research
- Orphazyme - Financial overhang removed by Danske Bank Equity Research